Supplementary Online Content

Mosher CL, Nanna MG, Jawitz OK, et al. Cost-effectiveness of pulmonary rehabilitation among US adults with chronic obstructive pulmonary disease. *JAMA Netw Open.* 2022;5(6):e2218189. doi:10.1001/jamanetworkopen.2022.18189

**eTable 1.** Effect of Patient Characteristics and Number of Sessions on Costs and Effectiveness

**eTable 2.** Summary of Prior Cost-effectiveness Analyses

**eFigure.** Scatterplot for Probabilistic Sensitivity Analysis

This supplementary material has been provided by the authors to give readers additional information about their work.
### eTable 1. Effect of Patient Characteristics and Number of Sessions on Costs and Effectiveness

| Parameter            | PR          | No PR        | Incremental* |
|----------------------|-------------|--------------|--------------|
|                      | Cost | QALY | Cost | QALY | Cost | QALY |
| Sex                  | NA   | NA   | NA   | NA   | NA   | NA   |
| Male                 | $54,742 | 6.48 | $60,299 | 6.01 | -$5,557 | 0.47 |
| Female               | $59,185 | 7.46 | $64,235 | 6.92 | -$5,050 | 0.54 |
| Age                  | NA   | NA   | NA   | NA   | NA   | NA   |
| 65                   | $72,266 | 9.82 | $79,115 | 9.62 | -$6,849 | 0.20 |
| 75                   | $54,442 | 6.18 | $61,804 | 6.06 | -$7,362 | 0.12 |
| 85                   | $42,795 | 4.18 | $50,379 | 4.09 | -$7,584 | 0.09 |
| GOLD Stage           | NA   | NA   | NA   | NA   | NA   | NA   |
| 2                    | $65,775 | 9.77 | $70,949 | 8.91 | -$5,174 | 0.86 |
| 3                    | $54,307 | 6.64 | $58,745 | 6.19 | -$4,438 | 0.45 |
| 4                    | $50,654 | 4.98 | $58,976 | 4.87 | -$8,233 | 0.11 |
| Number of PR Sessions| NA   | NA   | NA   | NA   | NA   | NA   |
| 10                   | $55,835 | 7.42 | $63,875 | 6.89 | -$8,040 | 0.53 |
| 25                   | $57,617 | 7.42 | $63,875 | 6.89 | -$6,258 | 0.53 |
| 36                   | $58,730 | 7.42 | $63,875 | 6.89 | -$5,145 | 0.53 |

*PR relative to No PR

### eTable 2. Summary of Prior Cost-effectiveness Analyses

| Outpatient PR program | Population | Study size | Study Design | Costs Included                                                                 | Time Horizon | Reference |
|-----------------------|------------|------------|--------------|---------------------------------------------------------------------------------|--------------|-----------|
| 3 sessions per week for 6 weeks | United Kingdom | 200 subjects majority with COPD | RCT | PR program, patient co-pays, outpatient visits and hospitalizations | 12 months | Griffiths et al, 16, 2001 |
| 2 sessions per week for 4 months | Netherlands | 199 GOLD stage 2 or 3 COPD subjects | RCT | PR program, Outpatient visits, hospitalizations, time off work, home care hours, travel expenses | 24 months | Hoogendoorn et al, 17, 2010 |
| 1 session per week for 8 weeks | Ireland | 350 COPD subjects | RCT | PR program, Outpatient visits, hospitalizations, time off work, home care hours | 22 weeks | Gillespie et al, 18, 2013 |
2-3 sessions per week for 6-8 weeks

Canada

210 completed PR; majority with COPD, 592 observational controls

Case vs control

PR program, Emergency visits, hospitalizations

12 months

Golmohammadi et al, 19, 2004

PR resulted in cost-savings and high QALYs in every iteration.

eFigure. Scatterplot for Probabilistic Sensitivity Analysis

© 2022 Mosher CL et al. *JAMA Network Open.*